The new frontier of hepatitis C virus (HCV)-mismatched heart and lung transplantation

Affiliations

¹ Department of Cardio-Thoracic Surgery, Policlinico S.Orsola Malpighi University Hospital, Bologna, Italy.
² Anesthesia & Intensive Care Medicine, Alma Mater Studiorum University of Bologna, Policlinico di S.Orsola, Bologna, Italy.

Editorial

Piergiorgio Solli et al. Ann Transl Med. 2019 Dec.

. 2019 Dec;7(Suppl 8):S279.

doi: 10.21037/atm.2019.11.123.

¹ Department of Cardio-Thoracic Surgery, Policlinico S.Orsola Malpighi University Hospital, Bologna, Italy.
² Anesthesia & Intensive Care Medicine, Alma Mater Studiorum University of Bologna, Policlinico di S.Orsola, Bologna, Italy.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Heart and Lung Transplants from HCV-Infected Donors to Uninfected Recipients.
Woolley AE, Singh SK, Goldberg HJ, Mallidi HR, Givertz MM, Mehra MR, Coppolino A, Kusztos AE, Johnson ME, Chen K, Haddad EA, Fanikos J, Harrington DP, Camp PC, Baden LR; DONATE HCV Trial Team. Woolley AE, et al. N Engl J Med. 2019 Apr 25;380(17):1606-1617. doi: 10.1056/NEJMoa1812406. Epub 2019 Apr 3. N Engl J Med. 2019. PMID: 30946553 Free PMC article. Clinical Trial.

Efficacy and safety of sofosbuvir-containing regimens in patients with chronic hepatitis C virus infection after liver transplantation: a meta-analysis.
Fu H, Dong J, Sun Z, Zhang X, Yu A, Chen G, Li W. Fu H, et al. Ann Transl Med. 2020 May;8(10):648. doi: 10.21037/atm-20-3074. Ann Transl Med. 2020. PMID: 32566585 Free PMC article.
Trends in use and three-year outcomes of hepatitis C virus-viremic donor lung transplants for hepatitis C virus-seronegative recipients.
Ruck JM, Zeiser LB, Zhou AL, Chidi AP, Winchester SL, Durand CM, Ha JS, Shah PD, Massie AB, Segev DL, Merlo CA, Bush EL. Ruck JM, et al. J Thorac Cardiovasc Surg. 2023 Apr;165(4):1587-1595.e2. doi: 10.1016/j.jtcvs.2022.08.019. Epub 2022 Sep 7. J Thorac Cardiovasc Surg. 2023. PMID: 36207160 Free PMC article.
A safety and efficacy analysis of direct-antiviral therapy in patients with chronic hepatitis C after renal transplantation.
Li G, Ma J, Xu L, Fang J, Zhang L, Wu J, Lai X, Liu L, Xiong Y, Yin W, Zhang T, Zhang P, Li L, Chen R, Wang J, Chen Z. Li G, et al. Transl Androl Urol. 2020 Apr;9(2):583-590. doi: 10.21037/tau.2020.01.05. Transl Androl Urol. 2020. PMID: 32420163 Free PMC article.

1. Reeb J, Keshavjee S, Cypel M. Expanding the lung donor pool: advancements and emerging pathways. Curr Opin Organ Transplant 2015;20:498-505. 10.1097/MOT.0000000000000233 - DOI - PubMed
1. Punch JD, Hayes DH, LaPorte FB, et al. Organ donation and utilization in the United States, 1996–2005. Am J Transplant 2007;7:1327-38. 10.1111/j.1600-6143.2007.01779.x - DOI - PubMed
1. Valapour M, Paulson K, Smith JM, et al. OPTN/SRTR 2011 annual data report: lung. Am J Transplant 2013;13:149-77. 10.1111/ajt.12024 - DOI - PubMed
1. Tian D, Wang Y, Shiiya H, et al. Outcomes of marginal donors for lung transplantation after ex vivo lung perfusion: A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2019. [Epub ahead of print]. 10.1016/j.jtcvs.2019.07.087 - DOI - PubMed
1. Mascia L, Pasero D, Slutsky AS, et al. Effect of a Lung Protective Strategy for Organ Donors on Eligibility and Availability of Lungs for Transplantation. A Randomized Controlled Trial. JAMA 2010;304:2620-7. 10.1001/jama.2010.1796 - DOI - PubMed